AstraZeneca PLC (AZN)
NYSE • Healthcare
May 26, 2026 at 18:08 UTC
About AstraZeneca PLC
AstraZeneca PLC is a biopharmaceutical company that discovers, develops, and supplies medicines used in hospitals and clinics around the world. The operating idea is steady and practical: move research through development, manufacture to consistent standards, and support appropriate use with clear guidance for clinicians. Programs focus on conditions that require long-term treatment and careful monitoring, so labeling, education, and supply planning sit close to scientific work. Country teams adapt access and information to local frameworks while holding to common safety principles. The purpose is to turn complex science into options that fit daily care, with availability that health systems can plan around rather than chase.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
AstraZeneca PLC's Technical Indicators Summary
AstraZeneca’s tape reads mildly bullish with the stock trading above its short- and medium-term averages and comfortably above the 200-day moving average, while the classic pivot is supportive. Momentum is mixed but not extreme — RSI near the mid-40s and neutral MACD — and ADX around 21 suggests a developing but not dominant trend. OBV is constructive, indicating positive volume support, and volatility is low with a sub-2% ATR. Technical takeaway: near-term bias is favorable, supported by moving-average positioning and positive volume, though trend strength is moderate.
| Indicator | Value |
|---|---|
RSI (14) | 49.36 |
Stochastic %K (14, 3, 3) | 58.66 |
CCI (20) | 55.23 |
WPR (14) | -9.63 |
Momentum (10) | 2.59 |
MFI | 56.38 |
MACD Level (12, 26) | -2.46 |
Bollinger Bands | $179.58 - $190.95 |
ATR (14) | $3.72 (1.98%) |
ADX (14) | 21.16 |
OBV | 48,071,670 |
Classic Pivot Point | $185.06 |
Fibonacci Pivot Point | $185.06 |
Exponential Moving Averages | $176.92 - $190.02(5 indicators) |
Simple Moving Averages | $179.84 - $192.32(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
A little upside push leaves AZN 0.58% above yesterday’s close (187.03), recent prints near 188.12. A supportive options backdrop emerges with PCR at 0.63, tilting slightly toward calls. AZN climbs on FDA clearance of Datroway for triple-negative breast cancer, with options showing a cautious call tilt.
Price Change
from $187.03 close
-$0.02
Trading Volume
Below avg (1.7M)
771.3K
vs S&P 500 Today
Outperforming Market
+0.64%
52-Week Position
Upper range
67.4%
Updated: May 26, 2026 at 16:42 UTC
Quote Summary
AZN Headlines
Big Pharma Updates: Trials, Deals and Ratings
April 27, 2026
Goldman’s Top Healthcare Picks Gain Fresh Catalysts
March 15, 2026
Moderna, Mexico sign mRNA vaccine pact
February 11, 2026